Literature DB >> 21789133

Practical considerations in ovarian cancer chemotherapy.

Mihaela Cristea1, Ernest Han, Lennie Salmon, Robert J Morgan.   

Abstract

Epithelial ovarian cancer remains the most lethal gynecologic malignancy despite advances in treatment. The standard management generally involves a combination of surgical tumor debulking and chemotherapy. Over the decades, chemotherapy for ovarian cancer has evolved and currently involves a combination of intravenous platinum and taxane chemotherapy. Over the past decade, three randomized phase III trials have been reported, and all have demonstrated a significant survival advantage for intraperitoneal compared with intravenous chemotherapy. However, there are potential barriers and controversies related to the administration of intraperitoneal chemotherapy in ovarian cancer patients. In this review, we discuss the evolution and current management considerations of chemotherapy for the treatment of epithelial ovarian cancer.

Entities:  

Keywords:  chemotherapy; intraperitoneal; ovarian cancer

Year:  2010        PMID： 21789133      PMCID： PMC3126016          DOI： 10.1177/1758834010361333

Source DB:  PubMed          Journal:  Ther Adv Med Oncol        ISSN： 1758-8340            Impact factor:   8.168


  59 in total

1.  Intraperitoneal chemotherapy for ovarian cancer: 2009 goals.

Authors:  Joan L Walker
Journal:  Gynecol Oncol       Date:  2009-03       Impact factor: 5.482

2.  Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG.

Authors:  Jacobus Pfisterer; Marie Plante; Ignace Vergote; Andreas du Bois; Hal Hirte; Angel J Lacave; Uwe Wagner; Anne Stähle; Gavin Stuart; Rainer Kimmig; Sigrid Olbricht; Tien Le; Janusz Emerich; Walther Kuhn; James Bentley; Christian Jackisch; Hans-Joachim Lück; Justine Rochon; Annamaria Hayden Zimmermann; Elizabeth Eisenhauer
Journal:  J Clin Oncol       Date:  2006-09-11       Impact factor: 44.544

3.  Improved therapeutic index of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide: final report by the Southwest Oncology Group of a phase III randomized trial in stages III and IV ovarian cancer.

Authors:  D S Alberts; S Green; E V Hannigan; R O'Toole; D Stock-Novack; P Anderson; E A Surwit; V K Malvlya; W A Nahhas; C J Jolles
Journal:  J Clin Oncol       Date:  1992-05       Impact factor: 44.544

4.  Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group.

Authors:  M Markman; B N Bundy; D S Alberts; J M Fowler; D L Clark-Pearson; L F Carson; S Wadler; J Sickel
Journal:  J Clin Oncol       Date:  2001-02-15       Impact factor: 44.544

5.  Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study.

Authors:  Robert F Ozols; Brian N Bundy; Benjamin E Greer; Jeffrey M Fowler; Daniel Clarke-Pearson; Robert A Burger; Robert S Mannel; Koen DeGeest; Ellen M Hartenbach; Rebecca Baergen
Journal:  J Clin Oncol       Date:  2003-07-14       Impact factor: 44.544

6.  Phase I feasibility and pharmacologic study of weekly intraperitoneal paclitaxel: a Gynecologic Oncology Group pilot Study.

Authors:  P Francis; E Rowinsky; J Schneider; T Hakes; W Hoskins; M Markman
Journal:  J Clin Oncol       Date:  1995-12       Impact factor: 44.544

7.  Cyclophosphamide plus cis-platinum in combination: treatment program for stage III or IV ovarian carcinoma.

Authors:  D G Decker; T R Fleming; G D Malkasian; M J Webb; J A Jeffries; J H Edmonson
Journal:  Obstet Gynecol       Date:  1982-10       Impact factor: 7.661

8.  Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup.

Authors:  Michael A Bookman; Mark F Brady; William P McGuire; Peter G Harper; David S Alberts; Michael Friedlander; Nicoletta Colombo; Jeffrey M Fowler; Peter A Argenta; Koen De Geest; David G Mutch; Robert A Burger; Ann Marie Swart; Edward L Trimble; Chrisann Accario-Winslow; Lawrence M Roth
Journal:  J Clin Oncol       Date:  2009-02-17       Impact factor: 44.544

9.  Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial.

Authors:  M K B Parmar; J A Ledermann; N Colombo; A du Bois; J-F Delaloye; G B Kristensen; S Wheeler; A M Swart; W Qian; V Torri; I Floriani; G Jayson; A Lamont; C Tropé
Journal:  Lancet       Date:  2003-06-21       Impact factor: 79.321

10.  Intraperitoneal cisplatin with systemic thiosulfate protection.

Authors:  S B Howell; C L Pfeifle; W E Wung; R A Olshen; W E Lucas; J L Yon; M Green
Journal:  Ann Intern Med       Date:  1982-12       Impact factor: 25.391
View more
  29 in total

Review 1.  Pegylated liposomal doxorubicin in the management of ovarian cancer: a systematic review and metaanalysis of randomized trials.

Authors:  Nicoletta Staropoli; Domenico Ciliberto; Cirino Botta; Lucia Fiorillo; Anna Grimaldi; Stefania Lama; Michele Caraglia; Angela Salvino; Pierfrancesco Tassone; Pierosandro Tagliaferri
Journal:  Cancer Biol Ther       Date:  2014-03-21       Impact factor: 4.742

Review 2.  Single compartment drug delivery.

Authors:  Michael J Cima; Heejin Lee; Karen Daniel; Laura M Tanenbaum; Aikaterini Mantzavinou; Kevin C Spencer; Qunya Ong; Jay C Sy; John Santini; Carl M Schoellhammer; Daniel Blankschtein; Robert S Langer
Journal:  J Control Release       Date:  2014-05-04       Impact factor: 9.776

3.  Targeting JAK1/STAT3 signaling suppresses tumor progression and metastasis in a peritoneal model of human ovarian cancer.

Authors:  Wei Wen; Wei Liang; Jun Wu; Claudia M Kowolik; Ralf Buettner; Anna Scuto; Meng-Yin Hsieh; Hao Hong; Christine E Brown; Stephen J Forman; David Horne; Robert Morgan; Mark Wakabayashi; Thanh H Dellinger; Ernest S Han; John H Yim; Richard Jove
Journal:  Mol Cancer Ther       Date:  2014-10-15       Impact factor: 6.261

4.  Enhancing delivery of small molecule and cell-based therapies for ovarian cancer using advanced delivery strategies.

Authors:  Joanne O'Dwyer; Roisin E O'Cearbhaill; Robert Wylie; Saoirse O'Mahony; Michael O'Dwyer; Garry P Duffy; Eimear B Dolan
Journal:  Adv Ther (Weinh)       Date:  2020-08-16

5.  A pharmacokinetic analysis of cisplatin and 5-fluorouracil in a patient with esophageal cancer on peritoneal dialysis.

Authors:  Jennifer R Eads; Jan H Beumer; Lavinia Negrea; Julianne L Holleran; Sandra Strychor; Neal J Meropol
Journal:  Cancer Chemother Pharmacol       Date:  2015-12-21       Impact factor: 3.333

6.  Use and Effectiveness of Intraperitoneal Chemotherapy for Treatment of Ovarian Cancer.

Authors:  Alexi A Wright; Angel Cronin; Dana E Milne; Michael A Bookman; Robert A Burger; David E Cohn; Mihaela C Cristea; Jennifer J Griggs; Nancy L Keating; Charles F Levenback; Gina Mantia-Smaldone; Ursula A Matulonis; Larissa A Meyer; Joyce C Niland; Jane C Weeks; David M O'Malley
Journal:  J Clin Oncol       Date:  2015-08-03       Impact factor: 44.544

Review 7.  Targeted therapy in ovarian cancer.

Authors:  Hui Jun Lim; William Ledger
Journal:  Womens Health (Lond)       Date:  2016-05-24

Review 8.  Comprehending the Proteomic Landscape of Ovarian Cancer: A Road to the Discovery of Disease Biomarkers.

Authors:  Shuvolina Mukherjee; Karin Sundfeldt; Carl A K Borrebaeck; Magnus E Jakobsson
Journal:  Proteomes       Date:  2021-05-25

9.  Efficacy and Safety of Systemic and Locoregional Cisplatin Chronotherapy in Rats with Ovarian Carcinoma.

Authors:  Galina Kireeva; Ekaterina Gubareva; Mikhail Maydin; Vladislav Osetnik; Stepan Kruglov; Andrey Panchenko; Anastasia Dorofeeva; Margarita Tyndyk; Elena Fedoros; Vladimir Anisimov
Journal:  Onco Targets Ther       Date:  2021-05-24       Impact factor: 4.147

10.  Paclitaxel resistance and multicellular spheroid formation are induced by kallikrein-related peptidase 4 in serous ovarian cancer cells in an ascites mimicking microenvironment.

Authors:  Ying Dong; Carson Stephens; Carina Walpole; Joakim E Swedberg; Glen M Boyle; Peter G Parsons; Michael A McGuckin; Jonathan M Harris; Judith A Clements
Journal:  PLoS One       Date:  2013-02-25       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.